Floatz logo

Eltrombopag

Acute Myeloid Leukemia

French Innovative Leukemia OrganisationSmall moleculePhase 2/3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
59/ 100

Competitive context

587 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
AKLAVINE
Chinese PLA General Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Eltrombopag is also rated in:

thrombocytopeniaActive
BB
Indicative · Phase 4
71 / 100
View asset →
hepatitis C virus infectionDormant
B
Indicative · Phase 3
56 / 100
View asset →
liver disorderDormant
B
Indicative · Phase 3
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →